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IntrOductIOn
Diabetes mellitus is the most common cause of chronic renal 
failure and end stage renal disease worldwide. Microvascular and 
macrovascular complications of diabetes increase cardiovascular 
and overall mortality [1]. Diabetic nephropathy occurs in about 
30%-35% of patients with type 1 and type 2 diabetic patients. After 
5-10 years, some diabetic patients have micro albuminuria that 
means urine albumin is between 30 and 300 mg/day [2,3]. After 
additional 5-10 years, macroalbuminuria (urine albumin ≥300 mg/
day) developed and at the time being glomerular filtration rate (GFR) 
began to decline at the rate of 10-12 ml/year. Advanced glycosylation 
end products (AGES), oxidative stress and hypertension are the 
main causes of pathophysiologic changes that lead to diabetic 
nephropathy [4,5]. In addition, inhibition of vascular dilation factors 
that decrease production or release of EDRF (Endothelium-derived 
relaxing factor) also may have a role in the intonation or augmentation 
of diabetic nephropathy. Deficiency of nitrous oxide (NO) that is a 
vasodilation factor releasing by vascular endothelium also have a role 
in this regard. Decrease in the production of nitrous oxide synthase 
(NOS) may lead to decline of NO and vascular dilation. ENOS is 
an important enzyme that contribute in vascular homeostasis, 
so eNOS gen located on chromosome 7 and has 26 exon [6,7]. 
Gen polymorphism of ACE (Angiotensin Converting Enzyme) was 
reported to have a basic role in diabetic nephropathy [8]. DD allele 
of ACE gene has been reported with development and severity of 
diabetic nephropathy and more rapid progression to end stage renal 
disease [9]. For example in a study on 109 type 2 diabetic patients, 
there was a positive association between the D allele of the ACE 
polymorphism and proteinuria [10]. Although there is a controversy 
in the results of studies, so some studies with large sample size 
could not find this correlation in specific races [11]. Correlation 
between polymorphism of some allele of eNOS gene and diabetic 
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ABStrAct
Background: Nephropathy is the most important leading cause 
of end stage renal failure in type 2 diabetic patients, so numerous 
studies were done to diagnose and evaluate risk factors of 
diabetic nephropathy (DN). Some gene polymorphisms may be 
associated with progression or regression of DN, so the aim of this 
study was to compare prevalence of eNOS gene polymorphism 
in diabetic patients with controls and its association with diabetic 
nephropathy.
Materials and Methods: In a cross-sectional study, 94 type 
2 diabetic patients and 94 normal participants were enrolled. 
Patients without retinopathy were excluded from this study. For all 
of the patients, fasting blood sugar (FBS), 2 hours post-prandial 
(BS), Blood Urea Nitrogen (BUN), Creatinine (Cr), 24 hours urine 
protein were measured in the case group. Endothelial nitric oxide 
synthetase gene polymorphism was evaluated in the case and 
control groups.
results: There was no significant difference based on age and 
sex between patients in case and control groups. GG genotype of 
eNOS was less common in the patient group compared to control 
group. There was no difference between prevalence of TT, GT or 
GG genotype based on age and sex. There was no correlation 
between diabetic retinopathy or proteinuria and genotypes of 
eNOs.
conclusion: The study showed that in type 2 diabetic patients, 
NOS gene polymorphism was more common compared to normal 
population; however, there is no correlation between this gene 
polymorphism and proteinuria or retinopathy in these patients.
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nephropathy and its severity has been also reported in other studies 
[12-14]. Based on our knowledge, there are a few studies in Iran 
especially in special races such as Lor on this issue. So, the aim of 
this study was to evaluate eNOS gene polymorphism with diabetic 
nephropathy and compare it among normal individuals.
MAterIAlS And MethOdS
In a cross-sectional study, in Imam Ali clinic of Shahrekord, Iran, 
100 diabetic patients and 100 normal participants were enrolled. 
All of the patients were among Lor tribe (Bakhtiari) that are one 
of the great and noble people of Iran. Inclusion criteria were: age 
greater than 40 year and presence of diabetes mellitus based on 
American Diabetes Association definition [15]. Diabetic patients 
with hypothyroidism, congestive heart failure and patients who had 
contraindication for consumption of angiotensin converting enzyme 
inhibitors (ACEi) or angiotensin receptor blockers (ARBs) were 
excluded from this study. All of the patients evaluated based on 
diabetic retinopathy and patients without retinopathy were excluded 
from the study. For all of the patients, Fasting Blood sugar (FBS), 
2 hours post-prandial BS, Blood Urea Nitrogen (BUN), Creatinine 
(Cr), 24 hours urine protein were measured in case group by using 
Biotechnica Instruments (BT 3000) and Flame Photometer (Corning 
480) Nyocard Reader II. Body weights, high Body Mass Index (BMI) 
with formula of body weight/height2 were also measured in the 
patients. Consent form was filled in by al the patients.
dnA extraction and Polymerase chain reaction 
experiment
Three ml of blood sample was drawn from patients and stored in 
5ml EDTA vaccutainers at -20ºc. Then DNA extraction was done 
using standard phenol/chloroform method and the final DNA pellet 
was dissolved in 20 Ul ddH2O or TE. The quality of extracted 
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DNA was analyzed either by 0.7% agarose gel electrophoresis 
visualized by gel documentation imaging or UV spectrophotometry 
at 260/280 nm. Characteristics of forward and reverse primer were 
eNOS3-F: 5’-AGATGAAGGCAGGAGACAGTGG-3’ and eNOS3-R: 
CCATCCCACCCAGTCAATC-3’ respectively. 
Each PCR was performed in a 10 μL reaction containing the 
following reagents: 25 ng genomic DNA, 1 μL buffer (10 mMTris-HCl 
{pH 8.3}, and 1.5 mM MgCl2), 250 μM MgCl2, 1% DMSO (Sigma-
Aldrich, St. Louis, MO), 200 μMdNTPs, 0.5 μM primer set, and 1U 
Taq DNA polymerase (sinagen, Iran). The condition of PCR cycles 
was included: initial denaturation at 94°C for 5 min, followed by 30 
cycles of denaturation 94°C for 40 s, annealing 62°C for 90 s, and 
extension 72°C for 50 s, and a final extension at 72°C for 3 min. 
After confirming the achievement of the expected 262 bp band on 
0.7% gel electrophoresis and visualization, the PCR products were 
subjected to MboI enzyme digestion and the products were then 
subjected to analysis on 12.5% polyacrylamide gel electrophoresis 
(PAGE). The expected restriction fragments of 162 bp and 100 bp 
were observed on the PAGE after visualization by silver staining. 
Sequence analysis of the PCR products was performed using 
the same primers as PCR by the ABI Big Dye Terminator Kit v.3.1 
(Applied Biosystems, USA).
StAtIStIcAl AnAlySIS
For continuous variables, data were presented as means ± SD 
as well as median; and for categorical ones, as frequency with 
percentage. Comparisons between groups were done using the 
Chi-square test for categorical variables and independent t-test for 
continuous ones. Kruskal-Wallis test was used to comparing the 
variables of interest among different genotype, because our data 
didn’t meet the assumptions of the parametric analysis of variance. 
Statistical analysis was performed by SPSS and p-values <0.05 
were statistically significant.
reSultS
As 6 cases of each group could not follow the study, so this study 
continued and was done by 94 patients in each group. Age of the 
patients was 42 to 85 years with mean of 61.8±9.5 years. Thirty 
six (38.3%) of the patients were male and 58 (61.7%) were female. 
There was no significant difference based on age and sex between 
patients and control groups (p>0.05). Twenty six (27.7%) of the 
patients had proteinuria less than 150 mg (mean of 105.5mg) and 
the others had greater than 150 mg proteinuria per day. Some 
characteristics of the patients were mentioned in the [Table/Fig-1]. 
Frequency of eNOS genotype in the two groups of study was 
summarized in [Table/Fig-2]. Based on data in [Table/Fig-2], GG 
genotype was significantly less frequent in the patients compared 
to control group. 
There is no difference between prevalence of TT, GT or GG genotype 
based on age and sex in two groups of the patients [Table/Fig-3,4]. 
Diabetic retinopathy did not have any correlation with genotypes of 
NOs. We did not find any correlation among TT, GT or GG genotypes 
and 24 hours urine protein, FBS and 2 hours postprandial blood 
sugar [Table/Fig-5].
dIScuSSIOn
The study showed that NOS synthase gene polymorphism in type 2 
diabetes was more common compared to normal population but it 
was not found any correlation between this gene polymorphism and 
proteinuria or retinopathy in the patients.
T. Angeline in a study on 260 patients showed a correlation between 
NOS synthase and diabetes mellitus [16]. In a study on 400 
diabetic patients, an association between 3 eNOS polymorphism 
(894G>T, -786T>C, and 27-bp-VNTR) and diabetic nephropathy 
was found [17]. Ze-jun Ma et al., in a meta-analysis found a 
significant association between the eNOS-4b/a polymorphism 
and DN in Chinese population, but not in non-Asian populations 
[18]. Khamaisi showed that decreasing renal NOS activity at the 
progressive phase of diabetes is associated with a decline in 
neuronal NOS activity and protein expression [19]. In the Rippin 
et al., study on Type 1 diabetic patients, there was no correlation 
between NOs polymorphism and diabetic nephropathy, so their 
results have some similarity with our study [20]. El-Din reported 
that TT genotype of eNOS had association with increased risk 
of end stage renal disease in type 2 diabetic patients, so it may 
be a useful marker for identification of high risk diabetic patients 
[21]. Association of NOs gen polymorphism and retinopathy that 
is another microvascular complication of diabetes was reported 
by Bazzaz et al., [22]. Zintzaras et al., in a meta-analysis, showed 
that G894T NOs gen polymorphism is associated with diabetic 
nephropathy in East Asians patients [12]. In a systemic review, 
association of DN with eNOS 4b/a and T-786C gen polymorphism 
was reported by Dellamea et al., [23]. Bernhard et al., in their study 
Variable Minimum Maximum Mean ± Sd
Age(year) 42 85 61.80±9.50
BMI(Kg/m2) 20.48 42.97 28.60±4.52
SBP(mmHg) 100 210 146.60±24.95
DBP(mmHg) 60 120 87.18±13.61
Urine Protein(mg/day) 59 2438 589.80±627.20
FBS(mg/dl) 62 489 59±67
2HPPBS(mg/dl) 98 644 251.5±81.24
Serum Cr 0.50 5.90 1.41±0.799
[table/Fig-1]: Some characteristics of the patients in the study
Genotype Patients (n (%) Control (n (%) p
TT 58 (61.7) 62 (66)
0.047
 
GG 3 (3.2) 10 (10.6)
GT 33 (35.1) 22 (23.4)
[table/Fig-2]: Prevalence of eNOS gen polymorphism in the patients and control 
groups.
diabetic tt (n (%) GG (n (%) Gt (n (%) p
Retinopathy 30 (58.8) 2 (3.9) 19 (37.3)
0.863
 No Retinopathy 28 (65.1) 1 (2.3) 14 (32.6)
[table/Fig-3]: Gene polymorphism prevalence of the patients based on diabetic 
retinopathy.
Sample Variable tt (n (%) GG (n (%) Gt (n (%) p
Patients Male 26 (72.2) 1 (2.8) 9 (25)
0.25
  Female 32 (55.2) 2 (3.4) 24 (41.4)
Healthy Male 27 (65.9) 5 (12.2) 9 (22)
0.891
  Female 35 (66) 5 (9.4) 13 (24.5)
[table/Fig-4]: Gene polymorphism prevalence of the patients and healthy groups 
based on sex.
 
Variable 
tt GG Gt
p
 
Mean ± Sd 
(Median)
Mean ± Sd 
(Median)
Mean ± Sd 
(Median)
Age
61.6 ± 8.8  
(61.5)
65 ± 5 
(61)
61.9 ± 11.9 
(61)
0.722
Urine protein
616.4 ± 656.8 
(358)
 459 ± 502.2 
(221)
 554.8 ± 595.8 
(399)
0.91
Serum Cr
1.44 ± 0.81 
(1.18)
1.16 ± 0.07 
(1.14)
1.39 ± 0.78 
(1.1)
0.85
FBS
153.5 ± 55.8 
(144)
169.6 ± 50.5 
(158)
168.1 ± 85.5 
(138)
0.81
2hppBS
253 ± 70.2 
(245)
256 ± 23.39 
(269)
248.5 ± 101.8 
(221)
0.53
[table/Fig-5]: Association among some variables of interest and eNOS gene poly-
morphism in the patients group
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on type 1 and type 2 diabetic patients did not find that eNOS 
gene polymorphism plays a significant role in the development of 
diabetic nephropathy [24]. Huo P in Chinese population found an 
association between ACE and eNOS and diabetic nephropathy 
[25]. Rahimi in a study on 173 diabetic patients and 101 healthy 
cases found the significantly increasing risk of macroalbuminuria in 
the presence of either eNOS 4a or 894T allele, however, he could 
not find any association between concomitant presence of both 
alleles with increasing risk of macroalbuminuria [26]. In a study on 
albuminuric and normoalbuminuric diabetic patients by Cheema; in 
normoalbuminuric patients, eNOS -786 CC and C-b-G and C-b-T 
genotype were associated with loweranti-proteinuric response 
to ACEi agents. However, in macroalbuminuric patients, eNOS 
-786 CC, C-b-G and C-b-T and 27VNTR aa genotypes were 
associated with higher response to ACEi or ARB drugs [27]. In the 
patients with proliferative diabetic retinopathy, higher frequency 
of the eNOS was minor ‘4a’ allele than in control group that it 
was found by Cilenšek [28]. Cheema showed that eNOS gene 
polymorphism increase responsiveness in type 2 diabetic patients 
without nephropathy and decrease response in microalbuminuric 
patients [27]. 
In a study by Corapciogluin on 97 Turkish diabetic foot ulcer 
patients and 102 controls, it was reported a significant association 
between eNOS alleles in patients with atherosclerotic heart 
disease, because GT-TT alleles were significantly higher than the 
GG alleles [29].
Cause of the discrepancy between above studies may be due to 
different ethnicity of the study populations.
lIMItAtIOn
Cardinal limitation of the study was small sample size, so we 
recommended similar studies on larger number of the patients and 
evaluation of correlation between other gene polymorphisms and 
DM complications such as nephropathy, retinopathy, neuropathy 
and atherosclerosis.
cOncluSIOn
In conclusion, the study showed more common prevalence of 
eNOS synthase gene polymorphism in type 2 diabetic patients 
compared to normal population; however, there is no correlation 
between this gene polymorphism and proteinuria or retinopathy in 
these patients. 
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